Alina Markova, MD
Articles
Alina Markova, MD, on the Safety Profile of Topical Ruxolitinib for Cutaneous Chronic GVHD
May 25th 2022Alina Markova, MD, highlights the safety and tolerability of topical ruxolitinib INCB018424 phosphate 1.5% cream for patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Alina Markova, MD, on Topical Ruxolitinib Mechanism of Action in Cutaneous Chronic GVHD
May 19th 2022Alina Markova, MD, speaks to the mechanism of action of topical ruxolitinib INCB018424 phosphate 1.5% cream vs oral ruxolitinib and other topical therapies used in the treatment of non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Alina Markova, MD, on the Rationale for Assessing Topical Ruxolitinib in Cutaneous Chronic GVHD
May 13th 2022Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Alina Markova, MD, on Key Findings With Topical Ruxolitinib in Cutaneous Chronic GVHD
May 10th 2022Alina Markova, MD, highlights important findings from a study assessing topical ruxolitinib INCB018424 phosphate 1.5% cream as a treatment for non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
